Loading
A phase 2 trial of pembrolizumab and lenvatinib in lung cancer, run by Medical University Innsbruck, now recruiting.
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC is a phase 2, interventional study registered as NCT04875585 by Medical University Innsbruck, with a registry enrolment figure of 33 participants, started 2021-05-12 and due to reach its primary completion in 2023-12. Interventions recorded: neoadjuvant therapy with Pembrolizumab/Lenvatinib; Surgery; Adjuvant Treatment Phase. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition. Lung eligibility wording from the registry: "Histologically confirmed primary diagnosis of resectable NSCLC, stages IA3-IIIA (max". Sites: Austria. No results are recorded here; the registry entry is the source.
Shares Lenvatinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Pembrolizumab and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.